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Background: Parastomal hernia is a common complication of a colostomy. Ultimately, one-third of patients with a
parastomal hernia will need surgical correction due to frequent leakage or life-threatening bowel obstruction or
strangulation. However, treatment remains a challenge resulting in high recurrence rates. Two single center trials
demonstrated that the frequency of parastomal hernias decreases by prophylactic placement of a mesh around the
stoma at the time of formation. Unfortunately, both studies were small-sized, single-center studies and with these
small numbers less common complications could be missed which were the reasons to initiate a prospective
randomized multicenter trial to determine if a retromuscular, preperitoneal mesh at the stoma site prevents
parastomal hernia and does not cause unacceptable complications.
Methods: One hundred and fifty patients undergoing open procedure, elective formation of a permanent
end-colostomy will be randomized into two groups. In the intervention group an end-colostomy is created with
placement of a preperitioneal, retromuscular lightweight monofilament polypropylene mesh, and compared to a
group with a traditional stoma without mesh. Patients will be recruited from 14 teaching hospitals in the
Netherlands during a 2-year period. Primary endpoint is the incidence of parastomal hernia. Secondary endpoints
are stoma complications, cost-effectiveness, and quality of life. Follow-up will be performed at 3 weeks, 3 months
and at 1, 2, and 5 years. To find a difference of 20% with a power of 90%, a total number of 134 patients must be
included. All results will be reported according to the CONSORT 2010 statement.
Discussion: The PREVENT-trial is a multicenter randomized controlled trial powered to determine whether
prophylactic placement of a polypropylene mesh decreases the incidence of a parastomal hernia versus the
traditional stoma formation without a mesh.
Trial registration: The PREVENT-trial is registered at: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2018
Keywords: Parastomal hernia, Prophylactic, Prevention, Mesh, Colostomy* Correspondence: henkthijs@hotmail.com
1Department of Surgery, Canisius Wilhelmina Hospital, Nijmegen, The
Netherlands
Full list of author information is available at the end of the article
© 2012 Brandsma et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Brandsma et al. Trials 2012, 13:226 Page 2 of 6
http://www.trialsjournal.com/content/13/1/226Background
Colorectal cancer is, together with breast cancer, the most
common malignancy in the Netherlands. The incidence of
colorectal cancer was over 12,000 in the year 2009. About
28,000 patients have an enterostomy, of which roughly
60% to 70% have a colostomy (Dutch Cancer Registry,
Dutch Stoma Association). About half of the patients with
a colostomy develop a parastomal hernia [1,2].
Probably, the true incidence is underestimated because
many of these hernias are asymptomatic. Cingi et al.
showed that 52% of their patients with a colostomy had a
parastomal hernia at clinical examination, while additional
computed tomography yielded an incidence of 78% [3].
Symptoms include pain due to stretching of the ab-
dominal wall, leakage due to poor fitting appliances, skin
problems, and cosmetic complaints. Moreover, bowel
obstruction and strangulation of the hernia contents
may be life-threatening. Despite evolution of surgical
techniques, incidence rates have not declined the past
20 years [4].
Ultimately, one-third of the patients with a parastomal
hernia needs surgical correction [5,6]. Parastomal hernia
repair is challenging and results vary markedly between
techniques. Suture repair, narrowing the opening in the
fascia, is considered an obsolete procedure because the
recurrence rates are over 70%. Relocation of the stoma is
associated with a recurrence rate of 33% with an add-
itional risk of developing an incisional hernia in the mid-
line or at the old ostomy site of 20% [2,7-9]. Nowadays,
prosthetic repair is the gold standard of parastomal her-
nia repair. Several techniques have been developed having
similar results with respect to morbidity and recurrence
rate (Hansson et al., 2012 [10]). In the last decade, laparo-
scopic repair of PSH is developing. Basically two techni-
ques are used, the modified Sugarbaker technique and the
keyhole technique, of which the last seems to have a sig-
nificantly higher risk of recurrence.
Because of the high incidence, inconsistent results of
available data on parastomal repair and lack of sufficient
treatment options, surgeons started focusing on preven-
tion of the hernia with local reinforcement of the ab-
dominal wall using a prosthetic mesh. At time of writing
the PREVENT-trial protocol in 2009, only a few reports
on this topic were published.
Two recent reviews showed that parastomal hernias
can be prevented by the placement of a preperitoneal,
retromuscular mesh around the stoma [11,12]. Rando-
mized trials from Jänes and Serra-Aracil, both using a
light-weight polypropylene mesh in a preperitoneal
retromuscular position, found significantly more para-
stomal hernias in the group with a conventional
stoma (53.7%) as compared to the mesh group (14.8%;
P <0.001). Mesh related complications are rare. Serra
reported one patient with a peristomal infection and onewith a stenosis of the stoma. Jänes reported no mesh-
related complications.
The percentage of patients with a parastomal hernia
who required surgical intervention decreased in the
mesh group in comparison with the non-mesh group.
Both studies combined seven out of 29 patients who
developed a PSH in the non-mesh group required surgi-
cal repair versus none of the eight in the mesh group
with a PSH [13,14] (Additional file 1: Table S1).
Unfortunately the trials were small, 27 patients per
group. Although a meta-analysis offers compensation for
this flaw, sample size still be too small for detecting a
difference when events occur infrequent. With these
small numbers of patients less common complications
could be missed. Furthermore the risk of bias increases
due to a variability of clinical factors and non-uniform
reporting of clinical parameters such as stoma site, patient
characteristics, and type of surgery all contributed to the
heterogeneity. To make more reliable statements on the
actual decline of the incidence of PSHs, larger groups are
needed.




The aim of this single-blind, multicenter, randomized
controlled trial is to determine if parastomal herniation
is prevented by the prophylactic placement during open
surgery of a polypropylene mesh around a colostomy.
Patients are blinded and are not aware if mesh place-
ment did occur. Most surgeons will see their own
patients postoperatively in the outpatient clinic so
double blinding was not feasible and could not be guar-
anteed. Patients are randomized into two groups. In one
group a preperitoneal, retromuscular positioned poly-
propylene mesh is placed around the stoma. In the con-
trol group a conventional stoma is created.
It is hypothesized that mesh placement will reduce the
incidence of parastomal hernia of 30% down to 10%.
Primary endpoint
The primary endpoint is the incidence of parastomal
hernia, either symptomatic or asymptomatic. In the final
report, these two groups, symptomatic and asymptom-
atic will also be reviewed separately to see if there are
more asymptomatic hernia in the mesh group.
Secondary endpoints
Secondary endpoints are perioperative morbidity, includ-
ing stomal necrosis, stenosis, parastomal, or laparotomy
wound infections. Mortality, pain, quality of life, and
cost-effectiveness are other secondary endpoints that
will be analyzed.
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Based on available literature it is hypothesized that 30%
of patients will develop a parastomal hernia, the majority
in the first few years. Based on published data it is
assumed that parastomal hernia will occur in 10% in the
study group receiving the prophylactic mesh.
This study is powered to reveal significant differences
between the two study groups. With an Alpha error of
5% (two-sided) and a Beta error of 0.10 (power of 90%),
67 patients need to be included in each arm of the trial.
We decided to include a total of 150 patients which are
randomly allocated in both groups. Analysis of recorded
Prismant data estimate that 600 colostomies are con-
structed each year in the Netherlands. It is expected that
the inclusion period will take 30 months and 14 hospi-
tals are required to participate. The study started in the
spring of 2010.
Setting
Patients receiving a permanent end-colostomy in an
elective setting will be recruited from the following
centers:
Canisius Wilhelmina Hospital, Nijmegen; Radboud Uni-
versity Nijmegen Medical Centre, Nijmegen; Rijnstate
Hospital, Arnhem; Maxima Medisch Centrum, Veldhoven;
St Antonius Hospital, Nieuwegein; Catharina Hospital,
Eindhoven; AMC Amsterdam, Amsterdam; OLVG,
Amsterdam; University Medical Center Utrecht; Utrecht;
Isala Clinics, Zwolle; Erasmus Medical Center, Rotterdam;
Slingeland Hospital, Doetinchem; Medisch Spectrum
Twente, Enschede; Albert Schweitzer Hospital, Dordrecht,
The Netherlands.
The total trial period is estimated to be 7 years; the
recruitment period will be 2 years, followed by a 5-year
follow-up period.
Inclusion criteria
 Patients undergoing formation of a permanent end-
colostomy in an elective setting regardless of benign
or malignant disease.
 Age between 18 and 85 years.
 Signed informed consent.
 Able to understand the study questionnaires.
Exclusion criteria
 Expected survival <12 months.
 Stoma formation in an emergency setting.
 Formation of an ileostomy.
 Correction of a previous constructed
colostomy.
 Previous surgery at the colostomy site.Ethical considerations
This trial is conducted in accordance with the Declar-
ation of Helsinki and ‘Good Clinical Practice Guidelines’.
It is approved by the Medical Ethics Committee of Nij-
megen (CMO-ABR 22695). All local Medical Ethics
Committees approved the final protocol.
Patients willing to participate in the trial will be
provided with a patient information sheet and a recon-
sideration period. They will be included after written
informed consent is obtained.




All results will be reported according to the CONSORT
2010 statement.
Randomization
Randomization will be performed by telephone using
an interactive voice response system. Patients are ran-
domized by computer, treatment will be stratified and
blocked by center to ensure each center has similar
numbers of patients allocated to one of the two treat-
ment groups.
Safety and quality control
The trial coordinator will monitor all centers in order to
identify non-compliance to protocol and serious adverse
events (SAEs). SAEs are defined as any event leading to
major complications and/or prolonged hospital stay due
to the placement of the mesh. SAEs will be reported to
the Data Safety Monitoring Board and to the accredited
Medical Ethical Board (METC).
A Data Safety Monitoring Board will perform interim
safety analyses and make recommendations regarding
the conduct of the study to the accredited METC and
the trial committee. When the mesh related complica-
tion rate is higher than 15%, the trial will be terminated.
Preoperative work-up
In an outpatient setting all participants receive informa-
tion and guidance by a stomal therapy nurse. Stoma site
marking is performed by a stomal therapy nurse prior to
surgery. Colonic lavage will be performed if necessary.
In both groups preoperative antibiotic prophylaxis will
be given according to the local agreements.
Surgical techniques
A light-weight monofilament polypropylene mesh, Parie-
tene Light™ (CovidienW) is the mesh of choice for this
study. This mesh is chosen because there is level 2b evi-
dence that shrinkage of the mesh, postoperative foreign
Figure 2 Cross-section through the abdominal wall. The mesh is
placed in the retromuscular plane on the posterior rectus sheath/
peritoneum. The bowel is passed through the pre-shaped hole in
the mesh and the rectus muscle. With the closure of the abdominal
wall the mesh and the peritoneum are included in the
running suture.
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traditional polypropylene mesh [15,16].
According to the technique of Jänes and Israëlsson,
the intended bowel for the colostomy is closed with a
stapling device, thus minimizing the chance of contam-
ination. The trephine is created by excision of the skin-
oval at the preoperatively marked ostomy site. No
subcutaneous tissue is excised. After exposing the anter-
ior rectus sheath, a cross-shaped incision is made in the
fascia. The rectus abdominus muscle is split in the direc-
tion of the fibers. In the mesh group a retromuscular
space is created and dissected to the lateral border via
the median laparotomy. The posterior fascia/peritoneum
is left undisturbed. A 10×10 cm Parietene Light™ mesh,
with a cross-shaped incision in the center of the pros-
thesis to allow passage of the colon loop, is placed on
the posterior rectus sheath (Figure 1).
The lateral corners of the mesh are fixed with two ab-
sorbable monofilament sutures. Then the posterior
fascia is opened over the trephine in the mesh and the
bowel is gradually passed through. Closing the midline
incision, the running suture includes the medial border
of the mesh and the peritoneum, thus preventing con-
tact between the mesh and the viscera (Figure 2). The
stoma has to protrude 1 to 2 cm above the skin and is
fixed with resorbable sutures to the skin [13].
This technique is described in detail in the study
protocol to ensure standardized mesh placement. It is
available in text and on video on our website: www.pre-
venttrial.nl.Follow-up and definitions of complications
Outpatient follow-up is scheduled at 3 weeks, 3 months,
1, 2 and 5 years postoperatively. Postoperative complica-
tions, such as peristomal infections, degree of stomal in-
growth, and leakage are recorded.
Parastomal hernia is defined as any detectable bulge in
the vicinity of the ostomy with the patient erect, supine,
and performing the Valsalva maneuver. Prolapse is
scored if significant prolabation of bowel occurred caus-
ing the stoma to increase in length without peri-stomalFigure 1 Preparing the central hole for the bowel to pass through, nobulging. Wound infection is defined in deep, superficial,
or peristomal infections using the C.D.C criteria for sur-
gical site infection [17].
Stomal dehiscence is defined as separation of the
bowel mucosa from the skin, measured in millimeters.
Stomal necrosis is defined as ischemia of the mucosal
tissue. Stenosis is defined as narrowing of the stomal
trephine leading to obstruction. Leakage is present if
stomal material has to be replaced more than once every
2 days.
If there is a clinical or physical suspicion of a hernia a
CT scan will be performed in a supine position with use
of the Valsalva maneuver.
Quality of life and postoperative pain is determined
using validated health scores preoperatively and during
all moments of follow-up after the index operation.central portion is cut away.
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 The SF-36 is a validated multi-purpose, short-form
health survey. It yields an eight-scale profile of
functional health and wellbeing scores as well as
physical and mental health summary measures and a
preference-based health utility index [18,19].
Completed preoperatively, 1 year, and 5 years after
index operation.
 Questionnaire of von Korff for Grading the Severity
of Chronic Pain [20]. Three months and 1 year after
the index operation.
 EuroQoL-5D is an instrument which calculates an
index which gives a societal-based quantification of
the patients health status combined with a visual
analogue scale [21]. This so-called health-related
quality of life (HRQoL) instrument will be
completed during every moment of follow-up. This
index gives a societal-based global quantification of
the patient’s health status.
Cost analysis
The cost analysis exists of two main parts. First, on pa-
tient level, volumes of care will be measured prospect-
ively using case record forms. Per arm (intervention and
control) full cost-prices will be determined using activity
based costing. Productivity losses for patients (sick leave)
will be estimated by using the case record forms (CRFs).
The friction cost-method will be applied following the
Dutch guidelines [22].
The second part of the cost analysis consists of deter-
mining the cost prices for each volume of consumption in
order to use these for multiplying the volumes registered
for each participating patient. The Dutch guidelines for
cost analyses will be used. For units of care/resources
where no guideline or standard prices are available real
cost prices will be determined.
Data collection
All data will be collected in personal CRFs, which will be
stored in the patient’s own hospital. Copies of the
completed forms will be sent to our coordinating center
(Canisius-Wilhelmina Hospital, Nijmegen). All data will
be stored in a double-entry database (SAS). Independent
monitoring visits will be performed throughout the entire
duration of the trial. When patients are not treated
according to their allocation, for any reason, they will stay
in the trial following the Intention-to-Treat-principle.Trial status
The PREVENT-trial is currently open for recruitment.
We expect to reach our powered number of included
patients in the coming months.Additional file
Additional file 1: Table S1. Data from all randomised controlled trials
regarding prevention of parastomal hernia’s (PSH) with a peristomal
retromuscular mesh [13,14].
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trial.
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